With two FDA-cleared platforms available, the technology is drawing clinicians interested in reaping its near-term benefits while preparing for its future impact.
The center will initially use the system for prostate, and head and neck cancers and in the future will let LabCorp patients access Mount Sinai pathologists.
While the first task of the centers will be to digitize their workflows to improve efficiency, they also aim to eventually develop new AI-based analytical tools for diagnosing patients.
Relying on artificial intelligence, the company has crafted a software tool to assist pathologists in diagnosing cancers and delivering clinical reports.
The platform is currently used by pathologists doing research and could be available in a year for primary diagnosis of cancers in clinical settings.
Oxford University Hospitals NHS Foundation Trust will use the Philips Intellisite system to create a digital pathology network across a number of UK hospitals.
The approval of the Philips Intellisite Pathology System by the Ministry of Food and Drug Safety follows US FDA clearance last year.
As Dana-Farber migrates its dozens of medical and radiation oncology protocols to the Philips platform, its focus is on digital pathology, genomics, and informatics.
The agreement grants MDxHealth the rights to manufacture and market the phosphodiesterase-4D7 biomarker as a prognostic test.
The Dutch multinational is now on track to introduce a kitted version of the assay, which can be run on standard quantitative PCR equipment, by the end of the year.